# Oncolytics Biotech Sets Clinical Data Timelines and Expects Final Grant Payment

- URL: https://stocks.freetheai.org/news/oncolytics-biotech-sets-clinical-data-timelines-and-expects-final-grant-payment-92a1a3
- Published: 2026-10-14T13:43:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:ONCY](https://stocks.freetheai.org/symbols/NASDAQ-ONCY)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Oncolytics Biotech Inc. (ONCY) expects to receive its final grant payment from the Pancreatic Cancer Action Network later this quarter as it completes wind-down activities for Cohort 5. The company has completed patient enrollment for its GOBLET trial and is winding down study infrastructure while continuing patient follow-up and data analysis.

The updates highlight clinical progress for pelareorep across multiple tumor types. In GOBLET Cohort 4, which evaluates pelareorep alongside atezolizumab in anal carcinoma, median overall survival has exceeded initial expectations. Clinical data from the study will guide future strategies to combine pelareorep with checkpoint inhibitors in gastrointestinal and other cancers.

Looking ahead, final results for Cohort 4 are expected in the fourth quarter of 2026. Initial data for Cohort 5, testing pelareorep with chemotherapy with or without atezolizumab in first-line metastatic pancreatic ductal adenocarcinoma, is anticipated in the first half of 2027, though timing could extend if patients stay on treatment longer. Shares of Oncolytics Biotech were up 3.53% at $0.49.

## Key points

- Oncolytics Biotech expects to receive the final PanCAN grant payment later this quarter as Cohort 5 wind-down activities conclude.
- Final trial results for GOBLET Cohort 4 in anal carcinoma are scheduled for release in the fourth quarter of 2026.
- Initial Cohort 5 data in first-line metastatic pancreatic cancer is targeted for the first half of 2027.
- Enrollment for the GOBLET study is complete, with median overall survival in Cohort 4 exceeding expectations.

## Questions and answers

### When will Oncolytics Biotech release GOBLET Cohort 4 results?

Oncolytics Biotech expects to report final results from GOBLET Cohort 4 in the fourth quarter of 2026.

### What is the timeline for Oncolytics Biotech Cohort 5 trial data?

Initial results for Cohort 5 are expected in the first half of 2027, though the schedule could extend as patients remain on treatment.

### What grant payment is Oncolytics Biotech expecting?

The company expects to receive its final Pancreatic Cancer Action Network grant payment later this quarter following Cohort 5 wind-down activities.